Wedbush Downgrades Surface Oncology to Neutral
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll has downgraded Surface Oncology (NASDAQ:SURF) from Outperform to Neutral.

June 20, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Surface Oncology (NASDAQ:SURF) has been downgraded from Outperform to Neutral by Wedbush analyst Robert Driscoll.
The downgrade from Outperform to Neutral by a Wedbush analyst indicates a change in the outlook for Surface Oncology. This could lead to a short-term negative impact on the stock price as investors may perceive the company as less attractive compared to its previous rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100